Anti‐CD20 mAb maintenance therapy showed no clear difference in overall survival compared with observation (moderate certainty).
Anti‐CD20 mAb maintenance therapy may leads to higher grade 3/4 adverse events compared with observation (low certainty).
Anti‐CD20 mAb maintenance therapy probably leads to lower progression‐free survival compared with observation (moderate certainty).
Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment‐related mortality compared with observation (low certainty).
Anti‐CD20 mAb maintenance therapy showed no clear difference in treatment discontinuation compared with observation (low certainty).
Anti‐CD20 mAb maintenance therapy may leads to higher all adverse events compared with observation (low certainty).